Start-Up Spotlight: Manus Neurodynamica Hopes To Write The End Of Traditional Parkinson’s Diagnosis
Executive Summary
Manus Neurodynamica intends to launch a pen, which provides early and accurate diagnosis of Parkinson’s disease, to the UK and Benelux markets and has £5m in funding to date.
You may also be interested in...
Trust And Talent In A Start-Up: A Two-Way Street
Rutger Zietsma, founder of Manus Neurodynamica and one of In Vivo's Rising Leaders of 2022, explains how his prior work guided his journey into executorship, and the issues of trust and talent in a start-up environment.
Interview: What Does Breakthrough Designation Mean For Manus Neurodynamica?
Medtech Insight spoke to Rutger Zietsma, Manus Neurodynamica’ CEO, to learn about the next commercial steps for the company's Neuromotor Pen for differential diagnosis of neuromotor impairment.
Exec Chat: Manus Neurodynamica Will Augment Pharmaceutical Companies’ Drug Trials
Simple-to-use devices capable of recording a plethora of data could be used to speed up drug trials and improve drug delivery, according to Rutger Zietsma, of Manus Neurodynamica.